{"nctId":"NCT01952015","briefTitle":"Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)","startDateStruct":{"date":"2013-08-21","type":"ACTUAL"},"conditions":["Psoriasis"],"count":12,"armGroups":[{"label":"AIN457","type":"EXPERIMENTAL","interventionNames":["Biological: Secukinumab"]}],"interventions":[{"name":"Secukinumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At baseline, presence of GPP classified on the basis of the criteria for diagnosis of GPP by Japanese Dermatological Association (JDA)\n* At baseline, erythema area with pustule ≥ 10%\n\nExclusion Criteria:\n\n* Erythrodermic, guttate psoriasis, or subcorneal pustular dermatosis at screening.\n* At baseline, : total score of JDA severity index for GPP ≥ 14\n* Drug-induced psoriasis\n* Ongoing use of prohibited psoriasis treatments.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Treatment Success at Week 16 Using Non-responder Imputation (Full Analysis Set)","description":"Treatment success was defined as \"Minimally improved\", \"Much improved\" or \"Very much improved\" in Clinical global impression (CGI).\n\nNon-responder imputation assigns a value of nonresponse to missing data points, any patient who drops out is assumed to be a non-responder.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Treatment Success at Week 52 Using Non-responder Imputation (Full Analysis Set)","description":"Ten patients showed treatment success at week 52 with clinical global impression (CGI) evaluated as \"very much improved\", \"much improved\", \"minimally improved\".\n\nTwo patients did not achieve treatment success at week 52 with CGI evaluated as \"missing\" and both were imputed as \"no treatment success\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Treatment Success at End of Trial Using Non-responder Imputation (Full Analysis Set)","description":"Clinical global impression (CGI) evaluated as \"very much improved\", \"much improved\", \"Minimally improved\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Clinical Global Impression up to End of Trial","description":"Clinical Global Impression (CGI) has five categories: Very much improved, much improved, minimally improved, no change and worsened.\n\nTwo patients did not achieve treatment success at week 52 with CGI evaluated as missing and both were imputed as \"no treatment success\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of JDA Total Score Category for GPP by Visit up to End of Trial","description":"Japanese dermatological association (JDA) severity index for generalized pustular psoriasis (GPP) included 3 categories (mild, moderate, and severe) in the severity index.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Japanese Dermatological Association (JDA) Component Score for GPP Over Time","description":"The following components of the JDA severity index for generalized pustular psoriasis (GPP) were reported: body surface area (SA)covered with total erythema with pustules, body SA covered with total erythema, body SA covered with edema, fever, white blood cell (WBC) count, C-reactive protein, serum albumin.\n\nThe total score of JDA severity index was assigned a score of 0-17. Assessment of skin lesions: area of erythema with pustules, area of erythema, and area of edema; each score 0-3. Assessment of systemic manifestations and laboratory findings: fever, WBC count, CRP and serum albumin; each score 0-2.\n\nThe higher the JDA severity index for GPP score the worse the outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.00"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Observed Value of Components of the JDA Severity Index for GPP","description":"The observed value for the following components of the JDA severity index for GPP were reported: percentage of body surface area covered with erythema with pustules, percentage of body surface area covered with total erythema, percentage of body surface area covered with edema, fever (body temperature,°C), white blood cell (WBC) count (/μL), C-reactive protein (mg/L), serum albumin (g/dL).\n\nPercent change=100 x Absolute change/post baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-89.09","spread":"33.001"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-100.00","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-100.00","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-63.56","spread":"46.693"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-83.60","spread":"24.442"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.01","spread":"15.826"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.92","spread":"107.200"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.17","spread":"69.733"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-99.05","spread":"2.520"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"1.071"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"1.076"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.87","spread":"1.473"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.16","spread":"23.120"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.16","spread":"28.009"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.63","spread":"18.838"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.12","spread":"197.270"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.21","spread":"245.564"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.60","spread":"146.990"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"7.952"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"12.952"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.64","spread":"3.688"}]}]}]},{"type":"SECONDARY","title":"Mean Health-related Quality of Life (The Dermatology Life Quality Index [DLQI] and Short Form Health Survey [SF-36]) Over Time","description":"DLQI is a 10-item general dermatology disability index designed to assess HRQL in adults with skin diseases (Finlay \\& Khan 94). The measure is self-admin. \\& includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. DLQI total score is the sum of the 10 questions. Each item has four response categories, ranging from 0 (not at all) to 3 (very much). Scores range from 0 to 30 9higher scores indicate greater health-related quality of-life impairment). SF-36 is a widely used and extensively studied instrument to measure HRQL among healthy subjects with acute \\& chronic conditions (Ware et al. 93, 94). It consists of 8 subscales (based on a scale of 0-100) that can be scored individually: Two overall summary scores for SF-36, the Physical Component Summary (PCS) and the Mental Component Summary (MCS), were computed. DLQI total score decreases and SF-36 increases with improvement of quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"6.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"5.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"2.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"8.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.69","spread":"17.472"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.70","spread":"9.9696"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.27","spread":"11.768"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.70","spread":"13.457"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.61","spread":"3.258"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.39","spread":"4.438"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.20","spread":"4.670"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.82","spread":"6.528"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With GPP-related Systemic and Topical Co-medication Over Time","description":"Use of systemic and topical co-medication to treat generalized pustular psoriasis (GPP), in subjects who have active GPP treatment at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":12},"commonTop":["NASOPHARYNGITIS","DIABETES MELLITUS","ARTHRALGIA","URTICARIA","ANAEMIA"]}}}